GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, tirzepatide/Mounjaro) are the fastest-growing drug class of the 2020s. Real adverse event reports exist in FDA FAERS data — including thyroid concerns, pancreatitis, and suicidal ideation reports — and are publicly available. Large peer-reviewed clinical trials (NEJM SELECT 2023, SURMOUNT-1 2022) have found these side effects either absent at statistically significant levels or outweighed by cardiovascular benefit. The conspiracy claim that pharma is deliberately hiding life-threatening side effects contradicts the publicly available clinical-trial data and FDA post-market surveillance, which are accessible to any researcher.